Homocysteine, vitamin determinants and neurological diseases

Frontiers in Bioscience - Scholar

Volumn 2 S, Issue 1, 2010, Pages 359-372

  Ientile, Riccardo ^a   Curro', Monica ^a   Ferlazzo, Nadia ^a   Condello, Salvatore ^a   Caccamo, Daniela ^a   Pisani, Francesco ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

Folate; Homocysteine; Neurodegenerative diseases; Review; Vitamin B12

Indexed keywords

HOMOCYSTEINE; VITAMIN B COMPLEX;

BLOOD; GENETIC POLYMORPHISM; GENETICS; HUMAN; HYPERHOMOCYSTEINEMIA; METABOLISM; NEUROLOGIC DISEASE; REVIEW; VASCULAR DISEASE; VITAMIN DEFICIENCY;

AVITAMINOSIS; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; NERVOUS SYSTEM DISEASES; POLYMORPHISM, GENETIC; VASCULAR DISEASES; VITAMIN B COMPLEX;

EID: 77957313066     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s70     Document Type: Article

References (147)

1. D. E. Wilcken: Novel risk factors for vascular disease: the homocysteine hypothesis of cardiovascular disease. J Cardiovasc Risk 5, 217-221 (1998) (Pubitemid 29030106)
2. H. Refsum, A. D. Smith, P. M. Ueland, E. Nexo, R. Clarke, J. McPartlin, C. Johnston, F. Engbaek, J. Schneede, C. McPartlin and J. M. Scott: Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 50, 3-32 (2004) (Pubitemid 38125696)
3. K. S. McCully: Hyperhomocysteinaemia and arteriosclerosis: historical perspectives. Clin Chem Lab Med 43, 980-986 (2005)
4. R. Christopher, D. Nagaraja and S. K. Shankar: Homocysteine and cerebral stroke in developing countries. Curr Med Chem 14, 2393-401 (2007) (Pubitemid 47618047)
5. H. Jakubowski: The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease. J Physiol Pharmacol 59, 155-167 (2008)
6. M. E. Temple, A. B. Luzier and D. J. Kazierad: Homocysteine as a risk factor for atherosclerosis. Ann Pharmacother 34, 57-65 (2000) (Pubitemid 30058925)
7. Homocysteine studies collaboration: Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288, 2015-2022 (2002)
8. A. Hassan, B. J Hunt, M. O'Sullivan, R. Bell, R. D'Souza, S. Jeffery, J. M. Bamford and H. S Markus: Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain 127, 212-219 (2004) (Pubitemid 38055360)
9. F. Van Dam, W.A. Van Gool: Hyperhomocysteinemia and Alzheimer's disease: A systematic review. Arch Gerontol Geriatr. 48, 425-30 (2009)
10. J. D. Spence: Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol 6, 830-838 (2007) (Pubitemid 47241275)
11. G. Gorgone, D. Caccamo, L. R. Pisani, M. Currò, G. Parisi, G. Oteri, R. Ientile, P. M. Rossini and F. Pisani: Hyperhomocysteinemia in patients with epilepsy: does it play a role in the pathogenesis of brain atrophy? A preliminary report. Epilepsia 50, Suppl 1, 33-36 (2009)
12. T. Suhara, K. Fukuo, O. Yasuda, M. Tsubakimoto, Y. Takemura, H. Kawamoto, T. Yokoi, M. Mogi, T. Kaimoto and T. Ogihara: Homocysteine enhances endothelial apoptosis via upregulation of Fas-mediated pathways. Hypertension 43, 1208-1213 (2004) (Pubitemid 38696913)
13. J. W. Heinecke: Biochemical evidence for a link between elevated levels of homocysteine and lipid peroxidation in vivo. Curr Atheroscler Rep 1, 87-89 (1999)
14. G. Ferretti, T. Bacchetti, C. Moroni, A. Vignini, L. Nanetti and G. Curatola: Effect of homocysteinylation of low density lipoproteins on lipid peroxidation of human endothelial cells. J Cell Biochem 92, 351-360 (2004)
15. S. Yalçinkaya, Y. Unlüçerçi, M. Giriş, V. Olgaç, S. Doǧru-Abbasoǧlu, M. Uysal: Oxidative and nitrosative stress and apoptosis in the liver of rats fed on high methionine diet: protective effect of taurine. Nutrition 25, 436-444 (2009)
16. E. Lubos, J. Loscalzo and D. E. Handy: Homocysteine and glutathione peroxidase-1. Antioxid Redox Signal 9, 1923-1940 (2007) (Pubitemid 47628605)
17. J. Folbergrová, R. Haugvicová, P. Mares: Behavioral and metabolic changes in immature rats during seizures induced by homocysteic acid: the protective effect of NMDA and non-NMDA receptor antagonists. Exp Neurol. 161, 336-345 (2000) (Pubitemid 30136555)
18. E. Ziemińska, A. Stafiej and J. W. Łazarewicz: Role of group I metabotropic glutamate receptors and NMDA receptors in homocysteine-evoked acute neurodegeneration of cultured cerebellar granule neurones. Neurochem Int 43, 481-492 (2003) (Pubitemid 36561303)
19. J. F. Toole, M. R. Malinow, L. E. Chambless, J. D. Spence, L. C. Pettigrew, V. J. Howard, E. G. Sides, C. H. Wang and M. Stampfer: Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291, 565-575 (2004) (Pubitemid 38500310)
20. K. H. Bønaa, I. Njølstad, P. M. Ueland, H. Schirmer, A. Tverdal, T. Steigen, H. Wang, J. E. Nordrehaug, E. Arnesen and K. Rasmussen; NORVIT Trial Investigators: Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354, 1578-1588 (2006)
21. L. A. Bazzano, K. Reynolds, K. N. Holder and J. He: Effect of folic acid supplementation on risk of cardiovascular diseases: a meta-analysis of randomized controlled trials. JAMA 296, 2720-2726 (2006) (Pubitemid 44917549)
22. S. J. Moat: Plasma total homocysteine: instigator or indicator of cardiovascular disease? Ann Clin Biochem 45, 345-348 (2008) (Pubitemid 352031539)
23. E. H. Reynolds: Vitamin B12, folic acid, and the nervous system. Lancet Neurol 5, 949-960 (2006)
24. A. N. Friedman, L.G. Hunsicker, J. Selhub, A.G. Bostom: Collaborative Study Group Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy. J Am Soc Nephrol. 16, 3397-402 (2005) (Pubitemid 46179343)
25. D. Shemin, A.G. Bostom, J. Selhub: Treatment of hyperhomocysteinemia in end-stage renal disease. Am J Kidney Dis. 38, S91-94 (2001)
26. S. R. Maxwell: Coronary artery disease - free radical damage, antioxidant protection and the role of homocysteine. Basic Res Cardiol 95, Suppl 1, I65-71 (2000)
27. M. W. Marlatt, P. J. Lucassen, G. Perry, M. A. Smith and X. Zhu: Alzheimer's disease: cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies. J Alzheimers Dis 15, 199-210 (2008)
28. L. M. de Lau, P. J. Koudstaal, J. C. Witteman, A. Hofman and M. M. Breteler: Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology 67, 315-318 (2006) (Pubitemid 44305422)
29. W. Herrmann, M. Herrmann and R. Obeid: Hyperhomocysteinaemia: a critical review of old and new aspects. Curr Drug Metab 8, 17-31 (2007) (Pubitemid 46043889)
30. B. Schwahn, R. Rozen: Polymorphisms in the methylenetetrahydrofolate reductase gene: clinical consequences. Am J Pharmacogenomics1, 189-201 (2001)
31. I. Weisberg, P. Tran, B. Christensen, S. Sibani and R. Rozen: A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64, 169-172 (1998) (Pubitemid 28453294)
32. A. Chango, F. Boisson, F. Barbe, D. Quilliot, S. Droesch, M. Pifster, N. Fillon-Emery, D. Lambert, S. Frémont, D. S. Rosenblatt and J. P. Nicolas: The effect of 677CT and 1298AC mutations on plasma homocysteine and 5, 10-methylenetetrahydrofolate reductase activity in healthy subjects. Br J Nutrition 83, 593-596 (2000) (Pubitemid 30392098)
33. Y. Berkun, D. Levartovsky, A. Rubinow, H. Orbach, S. Aamar, T. Grenader, I. Abou Atta, D. Mevorach, G. Friedman and A. Ben-Yehuda: Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 63, 1227-1231 (2004) (Pubitemid 39273498)
34. F. P. Cappuccio, R. Bell, I. J. Perry, J. Gilg, P. M. Ueland, H. Refsum, G. A. Sagnella, S. Jeffery and D. G. Cook: Homocysteine levels in men and women of different ethnic and cultural background living in England. Atherosclerosis 164, 95-102 (2002) (Pubitemid 34765642)
35. J. Robitaille, H. C. Hamner, M. E. Cogswell and Q. Yang: Does the MTHFR 677C->T variant affect the Recommended Dietary Allowance for folate in the US population?. Am J Clin Nutr 89, 1269-1273 (2009)
36. I. S. Weisberg, P. F. Jacques, J. Selhub, A. G. Bostom, Z. Chen, R. Curtis Ellison, J. H. Eckfeldt and R. Rozen: The 1298A3C polymorphism in methylenetetrahydrofolate reductase (MTHFR): in vitro expression and association with homocysteine. Atherosclerosis 156, 409-415 (2001) (Pubitemid 32522922)
37. L. Sharp and J. Little: Polymorphisms in genes involved in folate metabolism and colorectal neoplasia: a HuGE review. Am J Epidemiol 159, 423-443 (2004) (Pubitemid 38280289)
38. M. Y. Tsai, U. Garg, N. S. Key, N. Q. Hanson, A. Suh and K. Schwichtenberg: Molecular and biochemical approaches in the identification of heterozygotes for homocystinuria. Atherosclerosis 132, 69-77 (1996) (Pubitemid 26178095)
39. A. B. Guttormsen, P. M. Ueland, W. D. Kruger, C. E. Kim, L. Ose, I. Følling and H. Refsum: Disposition of homocysteine in subjects heterozygous for homocystinuria due to cystathionine beta-synthase deficiency: relationship between genotype and phenotype. Am J Med Genet 100, 204-213 (2001) (Pubitemid 32303919)
40. R. Clarke, L. Daly, K. Robinson, E. Naughten, S. Cahalane, B. Fowler and I. Graham: Hyperhomocysteinemia: an independent risk factor disease. NEJM 324, 1149-1155 (1991)
41. L. A. Kluijtmans, I. S. Young, C. A. Boreham, L. Murray, D. McMaster, H. McNulty, J. J. Strain, J. McPartlin, J. M. Scott and A. S. Whitehead: Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 101, 2483-2488 (2003) (Pubitemid 36857602)
42. D. J. Gaughan, L. A. Kluijtmans, S. Barbaux, D. McMaster, I. S. Young, J. W. Yarnell, A. Evans and A. S. Whitehead: The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 157, 451-456 (2001) (Pubitemid 32710025)
43. M. R. Hara and S. H. Snyder. Cell signaling and neuronal death. Annu Rev Pharmacol Toxicol 47, 117-141 (2007)
44. E. Besancon, S. Guo, J. Lok, M. Tymianski and E. H. Lo: Beyond NMDA and AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. Trends Pharmacol Sci 29, 268-275 (2008)
45. I. I. Kruman, C. Culmsee, S. L. Chan, Y. Kruman, Z. Guo, L. Penix and M. P. Mattson: Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci 20, 6920-6926 (2000)
46. A. A. Boldyrev and P. Johnson: Homocysteine and its derivatives as possible modulators of neuronal and nonneuronal cell glutamate receptors in Alzheimer's disease. J Alzheimers Dis 11, 219-228 (2007) (Pubitemid 47010983)
47. C. Hölscher: Possible causes of Alzheimer's disease: amyloid fragments, free radicals, and calcium homeostasis. Neurobiol Dis 5, 129-141 (1998) (Pubitemid 28520948)
48. P. Jenner: Oxidative stress in Parkinson's disease. Ann Neurol 53, S26-36 (2003)
49. I. I. Kruman, T. S. Kumaravel, A. Lohani, W. A. Pedersen, R. G. Cutler, Y. Kruman, N. Haughey, J. Lee, M. Evans and M.P. Mattson: Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 22, 1752-1762 (2002) (Pubitemid 35386293)
50. P. I. Ho, S. C. Collins, S. Dhitavat, D. Ortiz, D. Ashline, E. Rogers and T. B. Shea: Homocysteine potentiates beta-amyloid neurotoxicity: role of oxidative stress. J Neurochem 78, 249-253 (2001) (Pubitemid 32664406)
51. W. K. Kim and Y. S. Pae: Involvement of N-methyl-d-aspartate receptor and free radical in homocysteine-mediated toxicity on rat cerebellar granule cells in culture. Neurosci Lett 216, 117-120 (1996)
52. A. Grieve, S. P. Butcher and R. Griffiths: Synaptosomal plasma membrane transport of excitatory sulphur amino acid transmitter candidates: kinetic characterisation and analysis of carrier specificity. J Neurosci Res 32, 60-68 (1992)
53. K. Eto, T. Asada, K. Arima, T. Makifuchi and H. Kimura: Brain hydrogen sulfide is severely decreased in Alzheimer's disease. Biochem Biophys Res Commun 293, 1485-1488 (2002) (Pubitemid 34681045)
54. B. Regland, L. Abrahamsson, K. Blennow, B. Grenfeldt and C. G. Gottfries: CSF-methionine is elevated in psychotic patients. J Neural Transm 111, 631-640 (2004) (Pubitemid 38530069)
55. C. Isobe, T. Murata, C. Sato and Y. Terayama: Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. Life Sci 77, 1836-1843 (2005) (Pubitemid 41058987)
56. I. Guidi, D. Galimberti, S. Lonati, C. Novembrino, F. Bamonti, M. Tiriticco, C. Fenoglio, E. Venturelli, P. Baron, N. Bresolin and E. Scarpini: Oxidative imbalance in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol Aging 27, 262-269 (2006) (Pubitemid 43038550)
57. G. Topal, A. Brunet, E. Millanvoye, J. L. Boucher, F. Rendu, M. A. Devynck and M. David-Dufilho: Homocysteine induces oxidative stress by uncoupling of NO synthase activity through reduction of tetrahydrobiopterin. Free Radic Biol Med 36, 1532-1541 (2004) (Pubitemid 38746561)
58. H. Dawson, G. Collins, R. Pyle, V. Deep-Dixit and D. D. Taub: The immunoregulatory effects of homocysteine and its intermediates on T-lymphocyte function. Mech Ageing Dev 125, 107-110 (2004) (Pubitemid 38180555)
59. P. Zhang, C. Dilley and M. P. Mattson: DNA damage responses in neural cells: Focus on the telomere. Neuroscience 145, 1439-1448 (2007) (Pubitemid 46602741)
60. K. Schroecksnadel, B. Frick, C. Winkler, F. Leblhuber, B. Wirleitner and D. Fuchs: Hyperhomocysteinemia and immune activation. Clin Chem Lab Med 41, 1438-1443 (2003) (Pubitemid 37493558)
61. R. B. Effros, M. Dagarag and H. F. Valenzuela: In vitro senescence of immune cells. Exp Gerontol 38, 1243-1249 (2003) (Pubitemid 38043942)
62. M. De Martinis, C. Franceschi, D. Monti and L. Ginaldi: Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett 579, 2035-2039 (2005) (Pubitemid 40469666)
63. H. Dawson, G. Collins, R. Pyle, V. Deep-Dixit and D. D. Taub: The immunoregulatory effects of homocysteine and its intermediates on T-lymphocyte function. Mech Ageing Dev 125, 107-110 (2004) (Pubitemid 38180555)
64. M. P. Mattson, I. I. Kruman, W. Duan: Folic acid and homocysteine in age-related disease. Ageing Res Rev. 1, 95-111 (2002) (Pubitemid 38340354)
65. K. Schroecksnadel, B. Frick, C. Wirleitner, C. Winkler, H. Schennach and D. Fuchs: Moderate hyperhomocysteinemia and immune activation. Curr Pharm Biotechnol 5, 107-118 (2004) (Pubitemid 38410598)
66. A. F. van Raamt, S. Kalmijn, W. P. Mali, M. J. van Zandvoort and Y. van der Graaf, SMART Study Group: Homocysteine level and cognitive function in patients with arterial disease: the second manifestations of Arterial Disease Study. J Am Geriatr Soc 54, 575-579 (2006)
67. M. P. Mattson, I. I. Kruman and W. Duan: Folic acid and homocysteine in age-related disease. Ageing Res Rev 1, 95-111 (2002) (Pubitemid 38340354)
68. I. Picerno, C. Chirico, S. Condello, G. Visalli, N. Ferlazzo, G. Gorgone, D. Caccamo and R. Ientile: Homocysteine induces DNA damage and alterations in proliferative capacity of T-lymphocytes: a model for immunosenescence? Biogerontology 8, 111-119 (2007) (Pubitemid 46487980)
69. A. Fuso, L. Seminara, R. A. Cavallaro, F. D'Anselmi and S. Scarpa: S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 28, 195-204 (2005) (Pubitemid 39656023)
70. S. Oikawa, K. Murakami and S. Kawanishi: Oxidative damage to cellular and isolated DNA by homocysteine: implications for carcinogenesis. Oncogene 22, 3530-3538 (2003) (Pubitemid 36765312)
71. Y. T. Szeto and I. F. Benzie: Effects of dietary antioxidants on human DNA ex vivo. Free Radic Res 36, 113-118 (2002) (Pubitemid 34498556)
72. K. B. Vanizor, A. Orem, G. Cimsit, H. A. Uydu, Y. E. Yandi and A. Alver: Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta 332, 23-30 (2003) (Pubitemid 36577485)
73. T. M. Refai, I. H. Al Salem, D. Nkansa-Dwamena and M. H. Al Salem: Hyperhomocysteinaemia and risk of thrombosis in systemic lupus erythematosus patients. Clin Rheumatol 21, 457-461 (2002) (Pubitemid 36054441)
74. R. Roubenoff, P. Dellaripa, M. R. Nadeau, L. W. Abad, B. A. Muldoon, J. Selhub and I. H. Rosenberg: Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum 40, 718-22 (1997) (Pubitemid 27157578)
75. C. F. Sun, T. R. Haven, T. L. Wu, K. C. Tsao and J. T. Wu: Serum total homocysteine increases with the rapid proliferation rate of tumor cells and decline upon cell death: a potential new tumor marker. Clin Chim Acta 321, 55-62 (2002) (Pubitemid 34597053)
76. B. Widner, F. Leblhuber, B. Frick, A. Laich, E. Artner-Dworzak and D. Fuchs: Moderate hyperhomocysteinaemia and immune activation in Parkinson's disease. J Neural Trans 109, 1445-52 (2002) (Pubitemid 36057055)
77. N. Ferlazzo, S. Condello, M. Currò, G. Parisi, R. Ientile and D. Caccamo: NF-kappaB activation is associated with homocysteine-induced injury in Neuro2a cells. BMC Neurosci 9, 62 (2008)
78. D. Caccamo, A. Campisi, M. Currò, V. Bramanti, M. Tringali, G. Li Volti, A. Vanella and R. Ientile: Antioxidant treatment inhibited glutamate-evoked NF-kappaB activation in primary astroglial cell cultures. Neurotoxicology 26, 915-921 (2005) (Pubitemid 41427531)
79. R. Małek, K. K. Borowicz, M. Jargiełło and S. J. Czuczwar. Role of nuclear factor kappaB in the central nervous system. Pharmacol Rep 59, 25-33 (2007) (Pubitemid 46522699)
80. C. L. Allen and U. Bayraktutan: Risk factors for ischaemic stroke. Int J Stroke 3, 105-116 (2008) (Pubitemid 351566844)
81. R. L. Sacco: Identifying patient populations at high risk for stroke. Neurology 51, S27-30 (1998)
82. O. Bernal-Pacheco and G. C. Román: Environmental vascular risk factors: new perspectives for stroke prevention. J Neurol Sci 262, 60-70 (2007) (Pubitemid 47393678)
83. G. Saposnik, J. G. Ray, P. Sheridan, M. McQueen M and E. Lonn: Heart Outcomes Prevention Evaluation 2 Investigators. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke 40, 1365-1372 (2009)
84. D. H. Benninger, F. R. Herrmann, D. Georgiadis, R. Kretschmer, H. Sarikaya, A. Schiller, and R. W. Baumgartner: Increased prevalence of hyperhomocysteinemia in cervical artery dissection causing stroke: a case-control study. Cerebrovasc Dis 27, 241-246 (2009)
85. E. A. Angelova, P. A. Atanassova, N. T. Chalakova and B. D. Dimitrov: Associations between serum selenium and total plasma homocysteine during the acute phase of ischaemic stroke. Eur Neurol 60, 298-303 (2009)
86. R. H. Boger, S. M. Bode-Boger, A. Szuba, P. S. Tsao, J. R. Chan, O. Tangphao, T. F. Blaschke and J. P. Cooke: Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial Dysfunction its Role in Hypercholesterolemia. Circulation 98, 1842-1847 (1998) (Pubitemid 28509278)
87. S. R. Lentz, R. N. Rodionov and S. Dayal: Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. Atherosclerosis 4, 61-65 (2003) (Pubitemid 38234496)
88. M. L. Selley: Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol Aging 24, 903-907 (2003) (Pubitemid 36962974)
89. Q. Yang, L. D. Botto, J. D. Erickson, R. J. Berry, C. Sambell, H. Johansen and J. M. Friedman: Improvement in stroke mortality in Canada and the United States, 1990 to 2002. Circulation 113, 1335-1343 (2006) (Pubitemid 43739455)
90. X. Wang, X. Qin, H. Demirtas, J. Li, G. Mao, Y. Huo, N. Sun, L. Liu and X. Xu: Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 369, 1876-1882 (2007) (Pubitemid 46829358)
91. E. Lonn, S. Yusuf, M. J. Arnold, P. Sheridan, J. Pogue, M. Micks, M. J. McQueen, J. Probstfield, G. Fodor, C. Held and J. Jr Genest: Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354, 1567-77 (2006)
92. Y. Schwammenthal and D. Tanne: Homocysteine, B-vitamin supplementation, and stroke prevention: from observational to interventional trials. Lancet Neurol 3, 493-495 (2004) (Pubitemid 38903100)
93. O. P. Almeida, L. Flicker, N. T. Lautenschlager, P. Leedman, S. Vasikaran and F. M. van Bockxmeer: Contribution of the MTHFR gene to the causal pathway for depression, anxiety and cognitive impairment in later life. Neurobiol Aging 26, 251-257 (2005) (Pubitemid 39600581)
94. X. Huang, M. P. Cuajungco, C. S. Atwood, M. A. Hartshorn, J. D. Tyndall, G. R. Hanson, K. C. Stokes, M. Leopold, G. Multhaup, L. E. Goldstein, R. C. Scarpa, A. J. Saunders, J. Lim, R. D. Moir, C. Glabe, E. F. Bowden, C. L. Masters, D. P. Fairlie, R. E. Tanzi and A. I. Bush: Cu (II) potentiation of Alzheimer Abeta neurotoxicity correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 274, 37111-37116 (1999)
95. A. R. White, X. Huang, M. F. Jobling, C. J. Barrow, K. Beyreuther, C. L. Masters, A. I. Bush and R. Cappai: Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary neuronal cultures: possible risk factors in the Alzheimer's-type neurodegenerative pathways. J Neurochem 76, 1509-1520 (2001) (Pubitemid 32198255)
96. S. Seshadri, A. Beiser, J. Selhub, P. F. Jacques, I. H. Rosenberg, R. B. D'Agostino, P. W. Wilson and P. A. Wolf: Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346, 476-483 (2002) (Pubitemid 34441738)
97. M. Kivipelto, S. Annerbo, J. Hultdin, L. Bäckman, M. Viitanen, L. Fratiglioni, J. Lökk: Homocysteine and holo-transcobalamin and the risk of dementia and Alzheimers disease: a prospective study. Eur J Neurol 16, 808-813 (2009)
98. A. Fuso, L. Seminara, R. A. Cavallaro, F. D'Anselmi and S. Scarpa: S-adenosylmethionine/homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 28, 195-204 (2005) (Pubitemid 39656023)
99. S. Scarpa, A. Fuso, F. D'Anselmi and R. A. Cavallaro: Presenilin 1 gene silencing by S-adenosylmethionine: a treatment for Alzheimer disease. FEBS Lett 541, 145-148 (2003) (Pubitemid 36428933)
100. S. Scarpa, R. A. Cavallaro, F. D'Anselmi and A. Fuso: Gene silencing through methylation: an epigenetic intervention on Alzheimer disease. J Alzheimers Dis 9, 407-414 (2006) (Pubitemid 44253355)
101. P. A. Outinen, S. K. Sood, P. C. Liaw, K. D. Sarge, N. Maeda, J. Hirsh, J. Ribau, T. J. Podor, J. I. Weitz and R. C. Austin. Characterization of the stress-inducing effects of homocysteine. Biochem J 332, 213-221 (1998) (Pubitemid 28239337)
102. D. M. D'Emilia and S. A. Lipton: Ratio of S-nitrosohomocyst(e)ine to homocyst(e)ine or other thiols determines neurotoxicity in rat cerebrocortical cultures. Neurosci Lett 265, 103-106 (1999) (Pubitemid 29210379)
103. D. E. Handy, Y. Zhang and J. Loscalzo: Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation. J Biol Chem 280, 15518-15525 (2005) (Pubitemid 40616667)
104. G. Kronenberg, M. Colla and M. Endres: Folic acid, neurodegenerative and neuropsychiatric disease. Curr Mol Med 9, 315-323 (2009)
105. M. P. Mattson: Emerging neuroprotective strategies for Alzheimer's disease: dietary restriction, telomerase activation, and stem cell therapy. Exp Gerontol 35, 489-502 (2000) (Pubitemid 30665825)
106. J. Harada and M. Sugimoto: Activation of caspase-3 in beta-amyloid-induced apoptosis of cultured rat cortical neurons. Brain Res 842, 311-323 (1999) (Pubitemid 29475165)
107. S. Love, R. Barber and G. K. Wilcock: Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease. Brain 122, 247-253 (1999) (Pubitemid 29067207)
108. M. E. Smulson, C. M. Simbulan-Rosenthal, A. H. Boulares, A. Yakovlev, B. Stoica, S. Iyer, R. Luo, B. Haddad, Z. Q. Wang, T. Pang, M. Jung, A. Dritschilo and D. S. Rosenthal: Roles of poly(ADP-ribosyl)ation and PARP in apoptosis, DNA repair, genomic stability and functions of p53 and E2F-1. Adv Enzyme Regul 40, 183-215 (2000) (Pubitemid 30412535)
109. C. Culmsee, J. Monnig, B. E. Kemp and M. P. Mattson: AMP-activated protein kinase is highly expressed in neurons in the developing rat brain and promotes neuronal survival following glucose deprivation. J Mol Neurosci 17, 45-58 (2001) (Pubitemid 32928285)
110. G. Kronenberg, C. Harms, R. W. Sobol, F. Cardozo-Pelaez, H. Linhart, B. Winter, M. Balkaya, K. Gertz, S. B. Gay, D. Cox, S. Eckart, M. Ahmadi, G. Juckel, G. Kempermann, R. Hellweg, R. Sohr, H. Hörtnagl, S. H. Wilson, R. Jaenisch and M. Endres: Folate deficiency induces neurodegeneration and brain dysfunction in mice lacking uracil DNA glycosylase. J Neurosci 28, 7219-7230 (2008)
111. T.V. Bagnyukova, C.L. Powell, O. Pavliv, V. P. Tryndyak, I.P. Pogribny: Induction of oxidative stress and DNA damage in rat brain by a folate/methyl-deficient diet. Brain Res 1237, 44-51 (2008)
112. G. N. Welch and J. Loscalzo: Homocysteine and atherothrombosis. N Engl J Med 338, 1042-1050 (1998) (Pubitemid 128753793)
113. R. B. Postuma and A. E. Lang: Homocysteine and levodopa. should Parkinson disease patients receive preventative therapy? Neurology 63, 886-891 (2004) (Pubitemid 39297652)
114. L. M. de Lau, P. J. Koudstaal, J. C. Witteman, A. Hofman and M. M. Breteler: Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology 67, 315-318 (2006) (Pubitemid 44305422)
115. D. J. Stott, G. MacIntosh, G. D. Lowe, A. Rumley, A. D. McMahon, P. Langhorne, R. C. Tait, D. S. O'Reilly, E. G. Spilg, J. B. MacDonald, P. W. MacFarlane and R. G. Westendorp: Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. Am J Clin Nutr 82, 1320-1326 (2005) (Pubitemid 43779732)
116. K. Yasui, K. Nakaso, H. Kowa, T. Takeshima and K. Nakashima: Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand 108, 66-67 (2003) (Pubitemid 36791996)
117. P. O'Suilleabhain and R. Diaz-Arrastia: Levodopa elevates homocysteine: is this a problem? Arch Neurol 61, 633-634 (2004) (Pubitemid 38637676)
118. S. Zoccolella, P. Lamberti, E. Armenise, M. de Mari, S. V. Lamberti, R. Mastronardi, A. Fraddosio, G. Iliceto and P. Livrea: Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications. Parkinsonism Relat Disord 11, 131-133 (2005) (Pubitemid 40279156)
119. D. Caccamo, G. Gorgone, M. Currò, G. Parisi, W. Di Iorio, C. Menichetti, V. Belcastro, L. Parnetti, A. Rossi, F. Pisani, R. Ientile and P. Calabresi: Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients. Neuromolecular Med 9, 249-254 (2007) (Pubitemid 350129699)
120. D. Religa, K. Czyzewski, M. Styczynska, B. Peplonska, J. Lokk, M. Chodakowska-Zebrowska, K. Stepien, B. Winblad and M. Barcikowska: Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease. Neurosci Lett 404, 56-60 (2006) (Pubitemid 44063604)
121. Z. Todorovic, E. Dzoljic, I. Novakovic, D. Mirkovic, R. Stojanovic, Z. Nesic, M. Krajinovic, M. Prostran and V. Kostic: Homocysteine serum levels and MTHFR C677T genotype in patients with Parkinson's disease, with and without levodopa therapy. Journal of Neurological Sciences 248, 56-61 (2006) (Pubitemid 44647314)
122. E. S. Lee, H. Chen, K. F. Soliman and C. G. Charlton. Effects of homocysteine on the dopaminergic system and behavior in rodents. Neurotoxicology 26, 361-371 (2005) (Pubitemid 40780013)
123. S. Vurucu, E. Demirkaya, M. Kul, B. Unay, D. Gul, R. Akin and E. Gokçay: Evaluation of the relationship between C677T variants of methylenetetrahydrofolate reductase gene and hyperhomocysteinemia in children receiving antiepileptic drug therapy. Prog Neuropsychopharmacol Biol Psychiatry 32, 844-848 (2008) (Pubitemid 351312385)
124. D. Caccamo, S. Condello, G. Gorgone, G. Crisafulli, V. Belcastro, S. Gennaro, P. Striano, F. Pisani and R. Ientile: Screening for C677T and A1298C MTHFR polymorphisms in patients with epilepsy and risk of hyperhomocysteinemia. Neuromolecular Med 6, 117-126 (2004) (Pubitemid 41265781)
125. J. H. Yoo and S. B. Hong: A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants. Metabolism 48, 1047-1051 (1999) (Pubitemid 29374925)
126. H. Ono, A. Sakamoto, N. Mizoguchi and N. Sakura: Methylenetetrahydrofolate reductase 677C>T and epilepsy. J Inherit Metab Dis 23, 525-526 (2000)
127. T. Y. Tan, C. H. Lu, H. Y. Chuang, T. K. Lin, C. W. Liou, W. N. Chang and Y. C. Chuang: Long-term antiepileptic drug therapy contributes to the acceleration of atherosclerosis. Epilepsia 50, 1579-1586 (2009)
128. J. Folbergrová, V. Lisý, R. Haugvicová and F. Stastný: Specific [3H]glutamate binding in the cerebral cortex and hippocampus of rats during development: effect of homocysteine-induced seizures. Neurochem Res 22, 637-646 (1997) (Pubitemid 27184694)
129. V. Belcastro, G. Gaetano, D. Italiano, G. Oteri, D. Caccamo, L.R. Pisani, P. Striano, S. Striano, R. Ientile, F. Pisani. Antiepileptic drugs and MTHFR polymorphisms influence hyper-homocysteinemia recurrence in epileptic patients. Epilepsia. 48, 1990-1994 (2007) (Pubitemid 47537442)
130. S. Sahin, F. B. Aksungar, A. E. Topkaya, Z. Yildiz, U. T. Boru, S. Ayalp and S Karsidag: Increased plasma homocysteine levels in multiple sclerosis. Mult Scler 13, 945-946 (2007) (Pubitemid 351540868)
131. G. S. Ramsaransing, M. R. Fokkema, A. Teelken, A. V. Arutjunyan, M. Koch and J. De Keyser: Plasma homocysteine levels in multiple sclerosis. J Neurol Neurosurg Psychiatry 77, 189-192 (2006) (Pubitemid 43220840)
132. C. Russo, F. Morabito, F. Luise, A. Piromalli, L. Battaglia, A. Vinci, V. Trapani Lombardo, V. de Marco, P. Morabito, F. Condino, A. Quattrone and U. Aguglia: Hyperhomocysteinemia is associated with cognitive impairment in multiple sclerosis. J Neurol 255, 64-69 (2008)
133. B. Kocer, S. Engur, F. Ak and M. Yilmaz: Serum vitamin B12, folate, and homocysteine levels and their association with clinical and electrophysiological parameters in multiple sclerosis. J Clin Neurosci 16, 399-403 (2009)
134. H. McNulty and J. M. Scott: Intake and status of folate and related B-vitamins: considerations and challenges in achieving optimal status. Br J Nutr 99 Suppl 3, S48-54 (2008)
135. A. E. Czeizel: Folic acid and the prevention of neural-tube defects. N Engl J Med 350, 2209-2211 (2004) (Pubitemid 38638005)
136. T. Wolff, C. T. Witkop, T. Miller and S. B. Syed: Folic acid supplementation for the prevention of neural tube defects: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 150, 632-639 (2009)
137. C. L. Harden, P. B. Pennell, B. S. Koppel, C. A. Hovinga, B. Gidal, K. J. Meador, J. Hopp, T. Y. Ting, W. A. Hauser, D. Thurman, P. W. Kaplan, J. N. Robinson, J. A. French, S. Wiebe, A. N. Wilner, B. Vazquez, L. Holmes, A. Krumholz, R. Finnell, P. O. Shafer, C. L. Le Guen; American Academy of Neurology and American Epilepsy Society: Management issues for women with epilepsy - focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 50, 1247-1255 (2009)
138. J. Sauer, J. B. Mason and S. W. Choi: Too much folate: a risk factor for cancer and cardiovascular disease? Curr Opin Clin Nutr Metab Care 12, 30-36 (2009)
139. M. Endres, M. Ahmadi, I. Kruman, D. Biniszkiewicz, A. Meisel and K. Gertz: Folate deficiency increases postischemic brain injury. Stroke 36, 321-325 (2005) (Pubitemid 40170816)
140. J. M. Scott and D. G. Weir: Folic acid, homocysteine, and one-carbon metabolism: a review of the essential biochemistry. J Cardiovasc Risk 5, 223-227 (1998) (Pubitemid 29030107)
141. O. Stanger, W. Herrmann, K. Pietrzik, B. Fowler, J. Geisel, J. Dierkes and M. Weger: DACH-LIGA homocystein (German, Austrian and Swiss Homocysteine Society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 41, 1392-1403 (2003) (Pubitemid 37493551)
142. R. A. Swain and L. St. Clair: The role of folic acid in deficiency states and prevention of disease. J Fam Pract 44, 138-144 (1997) (Pubitemid 27087649)
143. J. H. Yoo, J. E. Park, K. P. Hong, S. H. Lee, D. K. Kim, W. R. Lee and S. C. Park: Moderate hyperhomocyst(e)inemia is associated with the presence of coronary artery disease and the severity of coronary atherosclerosis in Koreans. Thromb Res 94, 45-52 (1999)
144. M. S. Elkind and R. L. Sacco: Stroke risk factors and stroke prevention. Semin Neurol 18, 429-440 (1998) (Pubitemid 29058855)
145. A. Djukic: Folate-responsive neurologic diseases. Pediatr Neurol 37, 387-397 (2007) (Pubitemid 350087647)
146. M. P. Mattson and T. B. Shea: Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci 26, 137-146 (2003) (Pubitemid 36183675)
147. S. Zoccolella, I.L. Simone, P. Lamberti, V. Samarelli, R. Tortelli, L. Serlenga, G. Logroscino. Elevated plasma homocysteine levels in patients with amyotrophic lateral sclerosis. Neurology 70, 222-225 (2008)